Quantum Leap

Overview of the Quantum Leap program:

CQDM’s funding program for Quantum Leap biopharmaceutical research helps Canadian SMEs and universities undertake innovative translational R&D projects in collaboration with large biopharmaceutical organizations. The chosen projects aim to develop cutting-edge technologies with a potentially significant impact on the R&D activities of CQDM biopharmaceutical members. Quantum Leap projects are undertaken in close collaboration and with expert support and funding from our pharmaceutical members. Enabling technologies, pioneering platforms and/or innovative therapeutic methods developed should seek to improve, facilitate and/or considerably accelerate the discovery and development process for safer, more effective drugs. The technologies in question target all stages of drug development and cover a wide range of therapeutic indications. Projects are expected to generate tangible deliverables to be used by CQDM’s pharmaceutical members, once the project has been completed. Funded research offers researchers a perfect opportunity to secure future collaborations with the industry worldwide.

Benefits of the Quantum Leap program:

• Duration
• Minimum 1 year, maximum 3 years
• General funding parameters
• CQDM will assess funding applications for Quantum Leap biopharmaceutical research within the framework of the program, provided that you comply with the following parameters:
• Projects considered have a varying budget, usually between $500,000 to $1,500,000. As an exception, CQDM may assess applications over this limit when justified.
• Financial aid granted by CQDM usually represents one-third (1/3) of the total budget; however, the funding value and percentage may vary depending on the nature of the project in question.

Eligibility criteria of the Quantum Leap program:

• Canadian SMEs, Canadian university
• Researchers, public/private partnership
• Encouraged